Global contract development and manufacturing organization (CDMO) leader, Catalent Biologicals, is planning a $100 million expansion at their Madison, Wisconsin facility. The company develops and manufactures pharmaceutical products made from biological sources. Growth in Madison will accommodate increased capacity of mammalian cell culture products.
The 80,000 square foot addition in Madison will house 145 new employees. When the project is completed in mid-2021, total employment at the Madison operation will reach nearly 450. Company-wide, Catalent has more than 11,000 employees at over 30 facilities across five continents, and had $2.5 billion in revenue in fiscal 2018.